6 results about "Mitomycin C" patented technology

The invention belongs to the field of molecular biology, and particularly relates to a construction method and application of phosphorylation mutation sites of phosphoglucomutase. The mutation site is obtained by mutating threonine at the 144th site of escherichia coli wild-type phosphoglucomutase into aspartic acid, the sensitivity of an escherichia coli mutant strain with the mutation site to nalidixic acid, mitomycin C and tetracycline is remarkably improved, and the mutation site can be used for improving the sensitivity of bacteria to drugs.

This invention relates to the use of small molecule compounds that allosterically inhibit ALC1 (CHD1L), particularly two classes of ALC1 (CHD1L) allosteric inhibitors of formulas (I) and (II). When combined with inhibitors of several classes of cancer drugs, namely topoisomerase I, topoisomerase II, ATM, ATR, Wee1, BRD, and MEK, or when combined with mitomycin C, paclitaxel, ionizing radiation, or antibody-drug conjugates having tumor-specific antibodies conjugated to TOP1 inhibitors, the small molecule compounds and the allosteric inhibitors exhibit enhancing, preferably additive, effects in the treatment of proliferative diseases. Furthermore, this invention relates to the ALC1 inhibitor of formula (II), which, when combined with PARP inhibitors (poly(ADP-ribose)-polymerase inhibitors (PARPi)), exhibit synergistic effects in the treatment of pancreatic cancer or fallopian tube cancer. By synergizing with the functions of the aforementioned cancer drugs, the ALC1 inhibitors, particularly those of formulas (I) and (II) that enhance the cancer cell killing properties of the aforementioned cancer drugs, are particularly capable of achieving treatments in which any of the aforementioned inhibitors have already been used as part of standard care.

The invention belongs to the field of molecular biology, and particularly relates to a construction method and application of a phosphoenolpyruvate synthase T419D mutation site. The mutation site is obtained by mutating threonine at the 419th site of phosphoenolpyruvate synthase of an escherichia coli wild type into aspartic acid, the sensitivity of an escherichia coli mutant strain with the mutation site to nalidixic acid, mitomycin C and polymyxin sulfate B is remarkably improved, and the mutation site can be used for improving the sensitivity of bacteria to drugs.

The invention relates to the technical field of nano materials, in particular to catechol derivative ligands, gold nanoparticles modified by the catechol derivative ligands and application of the catechol derivative ligands. The catechol derivative modified gold nanoparticles provided by the invention can be used as a biological reducing agent, specifically, the specific value of GSH / GSSG in tumor cells is increased, the specific value of NADPH / NADP + is increased, the content of extracellular H2O2 is reduced, the content of GPx is increased, the content of MDA is reduced, and a reductive stress state is formed, so that the catechol derivative modified gold nanoparticles can be used as the biological reducing agent. In a reductive stress state, not only can the proliferation rate of tumor cells be inhibited, but also the mitomycin C can be activated, and the treatment effect of the mitomycin C on tumors can be improved.

The application discloses a molecular imprinting ratio type working electrode for detecting mitomycin C and a preparation method and application thereof, and belongs to the technical field of analysis and detection. The application aims to solve the problem of simple and accurate detection of the content of mitomycin C (MMC). The application adopts a solvothermal reaction to prepare cerium-nickel bimetallic organic framework material, adopts ultrasonic reaction to prepare cerium-nickel bimetallic organic framework / multi-walled carbon nanotube composite material, and adopts the cerium-nickel bimetallic organic framework / multi-walled carbon nanotube composite material and thionine as a modification material of an electrochemical sensing interface. A molecular imprinting ratio type electrochemical sensor with specific recognition response to a template molecule MMC is prepared on the surface of the modified electrode through an electrochemical polymerization method. The application is applied to the detection of the content of MMC, and has the advantages of simple operation, low cost, high sensitivity and good selectivity.

This invention relates to the field of nanomaterials technology, specifically to a catechol derivative ligand and its modified gold nanoparticles and their applications. The catechol derivative-modified gold nanoparticles provided by this invention can act as bioreducing agents, specifically by increasing the GSH / GSSG ratio and NADPH / NADP ratio in tumor cells. + By adjusting the ratio, reducing extracellular H2O2 content, increasing GPx content, and decreasing MDA content, a reducing stress state is formed, thus enabling it to act as a biological reducing agent. Under reducing stress, it can not only inhibit the proliferation rate of tumor cells but also activate mitomycin C, enhancing the therapeutic effect of mitomycin C on tumors.